German pharmaceutical company Bayer has announced the inauguration of its new life science incubator, Bayer Co.Lab Shanghai, in the Shanghai Innovation (SH-INNO) Park at the heart of China´s largest biopharma cluster, Zhangjiang, Shanghai.

Bayer Co.Lab is a part of the global network of life science incubators situated in key innovation hubs, including Cambridge (USA), Kobe (Japan), and Berlin (Germany). The establishment of Bayer Co.Lab Shanghai represents a major milestone in Bayer's external innovation strategy, aimed at fostering open collaboration within the biotechnology ecosystem.

The incubator will provide state-of-the art laboratories, collaborative working space and tailored support for startups, serving as a crucial pillar in advancing local innovation across the entire biopharmaceutical value chain.

With more than 140 years of presence in China, Bayer continues to expand its innovation footprint. To date, Bayer has established two global research & development (R&D) centres and four world-class production facilities in China. 

The launch of Bayer Co.Lab Shanghai underscores Bayer's continued commitment to investing in innovation in China and reinforces its determination to grow in this key market. Through Bayer Co.Lab, Bayer will deepen local partnerships and accelerate co-creation in China to drive healthcare innovation in China and globally.